Shire (SHP) Trading 0.2% Higher
Shire PLC (LON:SHP) traded up 0.2% during mid-day trading on Thursday . The stock traded as high as GBX 3,740 ($50.34) and last traded at GBX 3,685 ($49.60). 1,827,184 shares were traded during mid-day trading, a decline of 22% from the average session volume of 2,330,000 shares. The stock had previously closed at GBX 3,677.50 ($49.50).
Several equities research analysts have issued reports on the stock. J P Morgan Chase & Co reissued an “overweight” rating and issued a GBX 5,300 ($71.33) price target on shares of Shire in a report on Monday, October 30th. Liberum Capital lowered their price target on shares of Shire from GBX 4,400 ($59.22) to GBX 4,200 ($56.53) and set a “hold” rating on the stock in a report on Tuesday, October 24th. Deutsche Bank lowered their price target on shares of Shire from GBX 6,000 ($80.75) to GBX 5,700 ($76.72) and set a “buy” rating on the stock in a report on Tuesday, September 5th. Barclays reissued an “equal weight” rating and issued a GBX 4,000 ($53.84) price target on shares of Shire in a report on Monday, October 30th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a GBX 5,350 ($72.01) price target on shares of Shire in a report on Tuesday, August 22nd. Four investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Shire currently has a consensus rating of “Buy” and a consensus price target of GBX 5,277.78 ($71.03).
In other news, insider Anne Minto acquired 190 shares of the company’s stock in a transaction on Friday, September 29th. The stock was purchased at an average cost of GBX 3,785 ($50.94) per share, with a total value of £7,191.50 ($9,679.00).
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.